DNDN
{"sector":"Healthcare","industry":"Drugs","symbol":"DNDN","company_name":"Dendreon Corp","exchange":"NASDAQ"}DNDN Articles
Dendreon has committed the ultimate sin by filing for bankruptcy protection.
Published:
These are the top analyst upgrades and downgrades featured by 24/7 Wall St. for Monday, November 3, 2014.
Published:
Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.
Published:
ThinkstockDendreon Corp. (NASDAQ: DNDN) has turned into one of those unsettling biotech stories: It went from great promise, to high hopes, to a reality check, and now to an incredibly uncertain...
Published:
ThinkstockEarnings season is winding down and the markets remain choppy. Investors are wary, but they want upside and they keep hearing that this is now a stock picker’s market. 24/7 Wall St....
Published:
Dendreon is getting crushed, and the share price is down to levels not seen in a decade. The company's reported Provenge sales were again unimpressive. It feels like investor interest has died.
Published:
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
Published:
Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many of...
Published:
After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early March, especially in Celgene, Medivation and Pharmacyclics.
Published:
Biotech and emerging pharmaceutical stocks continue to be hot, but short sellers shied away from many of them in late February. Those bucking that trend include BioMarin Pharmaceutical and Medivation.
Published:
ThinkstockDendreon Corp. (NASDAQ: DNDN) remains a company in trouble. The post-earnings jump looked promising and investors probably took some comfort when shares popped from $2.88 up to $3.31....
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, March 4, 2014. The include Coca-Cola, Dendreon, Procter & Gamble, SunEdison and...
Published:
Shares of Dendreon moved higher Monday after the biotech company said it will start to market Provenge, its prostate-cancer drug, in Europe this year. Its fourth-quarter loss was smaller than...
Published:
After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical stocks in early February. The largest upswings happened to BioMarin...
Published:
24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January.
Published: